In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Invitae Corporation

https://www.invitae.com

Latest From Invitae Corporation

Invitae Acquires Genosity In $200M Deal, Raises $1.15Bn From Softbank Group

Invitae continues its growth initiative with a $1.15bn investment from Softbank Group and acquisition of Genosity to accelerate oncology testing.

Cancer Financing

Top 100 Outlook 2021: Medtechs Look To Build On Experiences Of Serving Global Markets In A Pandemic

Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.

Commercial Medical Device

Invitae And ArcherDX Will Merge To Create Comprehensive Cancer Testing Offering

The $1.4bn deal will combine Invitae’s centralized laboratory capabilities with ArcherDX’s precision oncology technologies.

Deals Cancer

Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017

Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.

Medical Device In Vitro Diagnostics
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Other Names / Subsidiaries
    • CombiMatrix Corporation
    • Clear Genetics
    • Diploid
UsernamePublicRestriction

Register